Literature DB >> 15247630

Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms.

Konrad Meissner1, Gabriele Jedlitschky, Henriette Meyer zu Schwabedissen, Peter Dazert, Lothar Eckel, Silke Vogelgesang, Rolf W Warzok, Michael Böhm, Christian Lehmann, Michael Wendt, Ingolf Cascorbi, Heyo K Kroemer.   

Abstract

OBJECTIVES: Variable expression of the ABC-type multidrug resistance membrane protein P-glycoprotein (P-gp, MDR1, ABCB1) in human heart is a potential modulator of drug effects or drug-induced cardiotoxicity. Expression of P-gp is known to be affected by single nucleotide polymorphisms in the MDR1 gene. Therefore, genotype-dependent expression of P-gp could be an important modulator of action of cardiac drugs.
METHODS: Heart tissue (auriculum) from 51 patients undergoing coronary artery bypass graft surgery was screened for genotype-dependent P-gp expression. P-gp was identified by immunoblotting and localized using immunohistochemistry. MDR1 mRNA was quantified by real-time PCR and immunohistochemistry and related to the MDR1 genotypes G2677T/A (Ala893Ser/Thr) and C3435T.
RESULTS: MDR1/18S rRNA mRNA copy numbers in heart auriculum were 3.48 +/- 2.25 x 10(-6) compared to 4.56 +/- 0.58 x 10(-6) in non-failing ventricular samples studied before. While the exon 26 C3435T genotype did not influence MDR1 mRNA expression, we found significantly elevated MDR1 mRNA expression in 10 patients carrying the exon 21 2677 AT or TT genotype as compared to 12 patients carrying the GG-variant with intermediate MDR1 mRNA expression in 29 heterozygous samples. P-gp was detected in the endothelial wall. Quantitative immunohistochemistry of protein expression, however, did not reveal significant influence of the studied SNPs.
CONCLUSION: The present study based on auricular samples suggests that genetic factors play a rather limited role in modulating P-gp expression in human heart. Therefore, the substantial interindividual variability in cardiac P-gp expression is likely related to environmental or disease related factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247630     DOI: 10.1097/00008571-200406000-00007

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  15 in total

Review 1.  Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.

Authors:  Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg
Journal:  Discov Med       Date:  2012-01       Impact factor: 2.970

Review 2.  Systems biology approaches to adverse drug effects: the example of cardio-oncology.

Authors:  Sherry-Ann Brown; Nicole Sandhu; Joerg Herrmann
Journal:  Nat Rev Clin Oncol       Date:  2015-10-13       Impact factor: 66.675

3.  Ethnicity-related polymorphisms and haplotypes in the human ABCB1 gene.

Authors:  Chava Kimchi-Sarfaty; Andrew H Marple; Shiri Shinar; Avraham M Kimchi; David Scavo; M Isabella Roma; In-Wha Kim; Adam Jones; Mili Arora; John Gribar; David Gurwitz; Michael M Gottesman
Journal:  Pharmacogenomics       Date:  2007-01       Impact factor: 2.533

Review 4.  Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.

Authors:  Stefan Wolking; Elke Schaeffeler; Holger Lerche; Matthias Schwab; Anne T Nies
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

Review 5.  Pharmacogenomics and histone deacetylase inhibitors.

Authors:  Andrew Kl Goey; Tristan M Sissung; Cody J Peer; William D Figg
Journal:  Pharmacogenomics       Date:  2016-10-21       Impact factor: 2.533

6.  Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.

Authors:  Anne M Noonan; Robin A Eisch; David J Liewehr; Tristan M Sissung; David J Venzon; Thomas P Flagg; Mark C Haigney; Seth M Steinberg; William D Figg; Richard L Piekarz; Susan E Bates
Journal:  Clin Cancer Res       Date:  2013-04-15       Impact factor: 12.531

Review 7.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

8.  Fetal polymorphisms at the ABCB1-transporter gene locus are associated with susceptibility to non-syndromic oral cleft malformations.

Authors:  Ardeshir Omoumi; Zihua Wang; Vincent Yeow; Yah-Huei Wu-Chou; Philip K Chen; Ingo Ruczinski; Joanne Cheng; Felicia S H Cheah; Caroline G Lee; Terri H Beaty; Samuel S Chong
Journal:  Eur J Hum Genet       Date:  2013-02-27       Impact factor: 4.246

9.  Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.

Authors:  Sukyung Woo; Erin R Gardner; Xiaohong Chen; Sandra B Ockers; Caitlin E Baum; Tristan M Sissung; Douglas K Price; Robin Frye; Richard L Piekarz; Susan E Bates; William D Figg
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

10.  Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines.

Authors:  Daniel L Hertz; Megan V Caram; Kelley M Kidwell; Jacklyn N Thibert; Christina Gersch; Nicholas J Seewald; Jeffrey Smerage; Melvyn Rubenfire; N Lynn Henry; Kathleen A Cooney; Monika Leja; Jennifer J Griggs; James M Rae
Journal:  Pharmacogenomics       Date:  2016-01-22       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.